Rituximab Mabion (rituximab)
- Region
- 🇪🇺 EU
- Active substance
- rituximab
- Company
- Mabion Spolka Akcyjna
- Status
- Application withdrawn
- Therapeutic area
- Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Arthritis, Rheumatoid; Microscopic Polyangiitis
- Application
- EMEA/H/C/005387
- ATC
- L01XC02
- Official record
- www.ema.europa.eu
Indication
Treatment of Non-Hodgkin's lymphoma (NHL), Chronic lymphocytic leukaemia (CLL).
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Riximyo Authorised · Sandoz GmbH
- 🇪🇺 Rixathon Authorised · Sandoz GmbH
- 🇺🇸 Zimrixby Approved · Dr Reddys Labs Sa
- 🇪🇺 Ruxience Authorised · Pfizer Europe MA EEIG
- 🇪🇺 MabThera Authorised · Roche Registration GmbH
- 🇪🇺 Blitzima Authorised · Celltrion Healthcare Hungary Kft.
- 🇪🇺 Truxima Authorised · Celltrion Healthcare Hungary Kft.
- 🇪🇺 Ituxredi Authorised · Reddy Holding GmbH
- 🇪🇺 Ritemvia Withdrawn · Celltrion Healthcare Hungary Kft.
- 🇪🇺 Rituzena (previously Tuxella) Withdrawn · Celltrion Healthcare Hungary Kft.
Follow Rituximab Mabion
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.